Michael Hopkins is a veteran journalist and editor, having spent 16 years in print and online media. His work includes 13 years as a managing and senior editor for various online news services operated by MediaBiz, including SkyREPORT, a top satellite industry news service.
In addition to MediaBiz, Michael has contributed articles to Light Reading, Satellite Business News and the SPECS newsletter from CableLabs, among other publications. In addition, he worked as a public relations professional with VisiTech PR, a firm focused on supporting technology clients in the United States and overseas. Michael also worked as a reporter for The Montrose Daily Press in Western Colorado.
Michael graduated from the University of Northern Colorado in 1992. He presently resides in Morrison, Colo., west of Denver.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I have always managed my portfolio and retired at 55 - as it turned out I could have done it 10 years sooner, but I was worried about putting the kids through college. Anyway, I don't need to be paid anymore, I just volunteer. Investing is my only paying job. I'm very interested in passive allocation strategies oriented toward non-correlated returns. But I still play around with some of my portfolio for fun. Active investing can be an interesting game, and money is a great way to keep score. While Seeking Alpha is a potential source of investment ideas (lots of sifting required), I find it much more useful in studying behavioral finance. It's very entertaining - tragedy and comedy almost every day.
With a focus on out-of-favor equities in the volatile high-technology, biotechnology, and natural resources sectors, we invest in companies with hidden deep value. The fund is led by a veteran researcher, whose core competency is in unraveling murky stories and strategically sifting through fundamentals.
With our experience, we hope to help readers discover alpha in areas most investors are not - or refuse to be - looking.
I hold a B.S. in Accounting.
"[T]he function of the margin-of-safety is, in essence, that of rendering unnecessary an accurate estimate of the future. If the margin is a large one, then it is enough to assume that future earnings will not fall far below those of the past in order for an investor to feel sufficiently protected against the vicissitudes of time."
"Needless to say, the analyst must take possible future changes into account, but his primary aim is not so much to profit from them as to guard against them. Broadly speaking, he views the future as a hazard which his conclusions must encounter rather than as the source of his vindication."
"[F]inding the really outstanding companies and staying with them through all fluctuations of a gyrating market proved far more profitable to far more people than did the more colorful practice of trying to buy them cheap and sell them dear…These opportunities did not require purchasing on a particular day at the bottom of a great panic."
I founded Seeking Alpha, and lead it for its first 10 years until I passed the CEO role to Eli Hoffmann. I started Seeking Alpha after working for five years as a technology research analyst for Morgan Stanley in New York. Seeking Alpha is now the dominant crowdsourced equity research platform.
I wrote the ETF Investment Guide (http://seekingalpha.com/article/15136-etf-investing-guide-one-page-summary-of-the-entire-guide), and I blog about startup best practices at http://davidjaxon.wordpress.com .
I have a B.A from Oxford University and an MSc from The London School of Economics, and am married with five children.
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship. I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech. I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
As a conservative, both politically and economically, I strive to look at the long term risks of all trades. I'm also in favor of and recognize the importance of implementing stop loss orders. When it comes to trading, the fear shouldn't be of failure, but the unwillingness to accept failure.
I have been involved in European investing funds for 20 years. Currently, I am a private investor interested in technology and biopharmaceutical stocks. My articles are based on my humble opinion and experience in the market. It is convenient for any investor who wants to invest in a stock to do due diligences.
I am an independent investor that has been successful trading small cap stocks. I look for stocks that can produce returns that far exceed the broader markets over a short period of time. Many of the stocks in which I take positions are high risk, high reward. I believe that buy and hold is dead and if you are not constantly looking for and finding what is moving in the market, you are better off staying out of the market. At times I will invest 100% of my discretionary trading capital into a single stock.
Rich Steffens has grown up in New Jersey, is a successful businessman, and follows social media trends amongst life science and biotech companies. His family is deeply influenced by the ill effects of diabetes, and is a kidney donor to his older sister. His area of interests also includes cancer immunotherapy, which he started writing about in 2008. Rich jokes that he is one of the world's slowest marathon runners, and he runs with MSKCCs Fred's Team to support cancer research, raising over $20,000 in ten years to support MSKCCs efforts.
Rich states- I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I seek to share and learn.
Writer and investor with an interest in most everything -- stocks, ETFs, commodities, and currencies. My background is in both economics and journalism so I try to present complex ideas clearly and concisely, but with a dash of creativity.